A5094258485- Cardiovascular Function and Risk Factors
- Cancer, Hypoxia, and Metabolism
- Peroxisome Proliferator-Activated Receptors
- Diet and metabolism studies
- Macrophage Migration Inhibitory Factor
- Diabetes Treatment and Management
- Nutrition and Health in Aging
- Parkinson's Disease Mechanisms and Treatments
- Pancreatic function and diabetes
- GDF15 and Related Biomarkers
- Microbial Metabolic Engineering and Bioproduction
University of Alberta
2024
Liraglutide, a glucagon-like peptide-1 receptor (GLP-1R) agonist used for the treatment of T2D, has been shown to alleviate diabetic cardiomyopathy (DbCM) in experimental which was associated with increased myocardial glucose oxidation. To determine whether this increase oxidation is necessary cardioprotection, we hypothesized that liraglutide’s ability DbCM would be abolished mice cardiomyocyte-specific deletion pyruvate dehydrogenase (PDH; Pdha1 CM−/− mice), rate-limiting enzyme Male and...
Growth differentiation factor 15 (GDF15) is a peptide with utility in obesity, as it decreases appetite and promotes weight loss. Because obesity increases the risk for type 2 diabetes (T2D) cardiovascular disease, imperative to understand actions of GDF15, especially since elevated GDF15 levels are an established biomarker heart failure. As loss should be encouraged early stages obesity-related prediabetes/T2D, where diabetic cardiomyopathy often present, we assessed whether treatment...